Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study - Wikidata - awgldk - TriplyDB

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

http://www.wikidata.org/entity/Q30278687

about

Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis.Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.Systemic amyloidosis: novel therapies and role of biomarkers.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Newer Therapies for Amyloid Cardiomyopathy.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.New concepts in the treatment and diagnosis of amyloidosis.Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.Light Chain Amyloidosis.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.Novel Therapies in Light Chain Amyloidosis.Recent advances in understanding and treating immunoglobulin light chain amyloidosis Deferred autologous stem cell transplantation in systemic AL amyloidosis

P2860

Q31095966-FE3C8157-5BBD-43C5-9466-FF662B6E7749 Q36965127-F3B42245-F2EF-4052-8324-DF984BBD76D2 Q36974379-D9EFE17B-2DCE-4D15-881C-6838674B4E1E Q37570615-880D346C-4A55-4EED-BC0E-7595F23D5400 Q38600436-2564654F-D132-4D25-B69B-E25F246183E0 Q38652107-1F71E716-880E-43EE-882F-15CB4C1ECE4E Q38663987-E6C2AE1F-D6E1-47F3-A493-61543A304851 Q38829923-625D65B4-5A39-45F2-9BCB-C2C424B2CA62 Q38917828-DE97E2F7-40AA-46B1-BFC6-DBD317719D41 Q38920614-C3165546-A10F-4A49-B30F-BA6702C00B7F Q38959241-BBE725FC-35A2-44C5-9180-982143098D7B Q40742235-3E06AF2E-2E0D-401C-87A7-CE2885F366A9 Q41433373-6B57DD16-5A67-4494-8256-AC5460EEE489 Q46048669-6B3A8560-88C3-457A-9470-94B8B703E245 Q47206472-227752B7-A9F4-4979-AAF7-7BFFA63ABAF4 Q47561519-EA7A94F9-518F-42C4-A2D9-0DC9D3A4093F Q47643557-C3865FDF-A692-4E03-9C5C-BAC7486D937B Q48139614-439CBF22-C4B7-49E0-8B8F-AAA9B7FA9D44 Q48614453-AF40BDD3-09A0-4009-AB6A-DD4BCD69ABE7 Q51786246-120D22C9-698C-4D65-9BFA-28526A450967 Q52659305-34CD7E80-0F45-4668-B1A8-779FB97B384B Q52716575-D405AA18-285B-4E74-9505-30961774567B Q52777488-81C50D93-71BC-40EE-BB6A-0BD1B700C49F Q55127439-0C0F0BE0-287C-4D00-AD7C-4E87F561A863 Q57166910-7AB575EA-3F7D-4CF6-A22E-76B6A6807A44 Q58609453-45FA8823-5182-48D9-AF12-D9193450C4A5

P2860

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

http://www.wikidata.org/entity/Q30278687

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@ast

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@en

type

label

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@ast

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@en

prefLabel

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@ast

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@en

P1433

Q30278687-E037F215-9548-437B-83A4-3564107129AF

P1476

Q30278687-1A2212A2-CBDA-4F61-85A1-5D5A87A01205

P2093

Q30278687-0EDCB79D-DCB5-43BD-AC6D-7F14DFDBBFF2

Q30278687-17A835E9-E904-45F9-B6B1-71F069F2E0F9

Q30278687-248EFDD7-DE9C-47BC-A3AF-18E606813EAF

Q30278687-2E4A92B6-12AF-4F08-B1A7-2E9C6913D56F

Q30278687-32735E92-429E-44BD-B5DF-C7D47656689C

Q30278687-34639FB1-4011-4190-86BB-B4BC656807D4

Q30278687-3CA38616-C1EF-40C0-B77E-335DD698589D

Q30278687-3F35486A-82CE-4470-9C9F-25E96E7E7A17

Q30278687-40DD4C65-04DC-44CC-A17C-46CA9672EB5F

Q30278687-785BE71B-67E5-49A6-950E-5F1E87112E55

P2860

Q30278687-0B9D49AF-35E1-425F-AD04-70981996ECBB

Q30278687-1834A6F4-AD8F-422E-8E71-8CAB6B6314B2

Q30278687-2A73FEAF-945C-42F7-B8C5-FA410F41D130

Q30278687-2A987830-CBC6-47BA-9017-01A2D6E36F90

Q30278687-2DF4AF9F-1EF6-4A20-93F9-29524E0621C9

Q30278687-431F0AE1-1598-4DB1-8D47-A27B4C66F347

Q30278687-47726DF4-AFEB-45AB-BC78-3AE996599719

Q30278687-5B522F67-8C4B-4E23-A025-1AADCB05C6E3

Q30278687-6BC3104B-65B9-4E76-AAD9-EE1EAEFBEB73

Q30278687-7FA8DB31-3580-44BC-9E19-108F3A50D679

P304

Q30278687-C7CC941D-3DF7-4F9C-BC4B-506BEFE3056C

P31

Q30278687-AD9CFD8F-DADB-4186-A5B7-0C3EF9A47F8D

P356

Q30278687-5D67E05E-0C6D-413A-AD1D-AEB387B2A806

P407

Q30278687-6D6FCC0A-D7F5-4DAB-8C06-F15E8654C055

P433

Q30278687-9B6F272A-B5EC-4DCA-90A9-FDD270C8EA86

P478

Q30278687-2353E0EC-C72D-44D3-A8EE-0AB8C602B2AB

P50

Q30278687-20E7ED62-9EF1-4626-8777-0E93A5882703

Q30278687-7536FD82-5BF3-4DF4-88FA-989B4C2417F3

Q30278687-CF44D167-7472-4868-87C9-80D5FE7BD8A9

Q30278687-DAE656E6-B63A-4307-AF60-31CCCA236621

Q30278687-F08C2B85-8B7E-4402-A18D-FB1B63AEA58A

P577

Q30278687-0347E4B7-AADD-4058-B1D7-0E0E1CB98574

P698

Q30278687-F2EDEAB3-B5DE-4026-9C84-54B14EF5202F

P932

Q30278687-7F5A796E-521D-4A99-B883-2A53AE2CBE0B

P356

JCO.2015.62.4015

P1433

Journal of Clinical Oncology

P1476

Improved Outcomes After Autolo ...... rrow Transplant Research Study

@en

P2093

Anita D'Souza

http://www.w3.org/2001/XMLSchema#string

Baldeep Wirk

http://www.w3.org/2001/XMLSchema#string

Bipin N Savani

http://www.w3.org/2001/XMLSchema#string

Brendan M Weiss

http://www.w3.org/2001/XMLSchema#string

César O Freytes

http://www.w3.org/2001/XMLSchema#string

Dan T Vogl

http://www.w3.org/2001/XMLSchema#string

Emma C Scott

http://www.w3.org/2001/XMLSchema#string

Heather J Landau

http://www.w3.org/2001/XMLSchema#string

Jan S Moreb

http://www.w3.org/2001/XMLSchema#string

Jiaxing Huang

http://www.w3.org/2001/XMLSchema#string

P2860

AL amyloidosis: the last 30 years.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.

Amyloidosis: pathogenesis and new therapeutic options.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

P304

3741-3749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.62.4015

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Robert Peter Gale

Angela Dispenzieri

Hillard M Lazarus

P577

2015-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26371138

http://www.w3.org/2001/XMLSchema#string

P932

4737858

http://www.w3.org/2001/XMLSchema#string